Viewing StudyNCT06131424

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
View Study With Definitions
Ignite Creation Date: 2024-05-06 @ 7:47 PM
Last Modification Date: 2024-10-26 @ 3:13 PM
Study NCT ID: NCT06131424
Status: RECRUITING
Last Update Posted: 2024-06-24
First Post: 2023-11-09
Brief Title: NIS Study Determining Prevalence of HER2-low in Metastatic Breast Cancer Patients
Sponsor: AstraZeneca
Organization: AstraZeneca
Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Conditions & Keywords Data

Conditions:
Name
HER2-negative
Keywords:
Name View
Subsets View
HER2 Low Metastatic breast cancer View
HRHormone Receptor IHCmmunohistochemistry View
ISH in situ hybridization View
Anticancer therapy View
Prognostic and Predictive Biomarker View
Formalin-fixed paraffin-embedded FFPE View
endocrine therapyET View